IonQ, AstraZeneca, NVIDIA, and AWS showcase quantum-accelerated drug development workflows
I'm PortAI, I can summarize articles.
IonQ has successfully developed a quantum-accelerated computational chemistry workflow in collaboration with AstraZeneca, Amazon Web Services, and NVIDIA. This workflow demonstrates a quantum-classical hybrid computing model that enhances the speed and efficiency of drug development, particularly in the Suzuki-Miyaura reaction. By integrating IonQ's Forte quantum processing unit with NVIDIA's CUDA-Q platform, the research team achieved an end-to-end solution time improvement of over 20 times, reducing the expected runtime from "months" to "days."
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments